Loading...
XNYSBAX
Market cap14bUSD
Dec 27, Last price  
29.20USD
1D
-0.34%
1Q
-24.96%
Jan 2017
-34.15%
Name

Baxter International Inc

Chart & Performance

D1W1MN
XNYS:BAX chart
P/E
5.61
P/S
1.01
EPS
5.20
Div Yield, %
3.93%
Shrs. gr., 5y
-1.51%
Rev. gr., 5y
5.89%
Revenues
14.81b
-1.99%
9,509,000,0009,849,000,00010,378,000,00011,263,000,00012,348,000,00012,562,000,00012,843,000,00013,893,000,00014,190,000,00015,259,000,00016,671,000,0009,968,000,00010,163,000,00010,561,000,00011,127,000,00011,362,000,00011,673,000,00012,784,000,00015,113,000,00014,813,000,000
Net income
2.66b
P
388,000,000956,000,0001,396,000,0001,707,000,0002,014,000,0002,205,000,0001,420,000,0002,224,000,0002,326,000,0002,012,000,0002,497,000,000968,000,0004,965,000,000717,000,0001,624,000,0001,001,000,0001,102,000,0001,284,000,000-2,421,000,0002,656,000,000
CFO
1.73b
+42.53%
1,380,000,0001,550,000,0002,183,000,0002,305,000,0002,515,000,0002,909,000,0003,003,000,0002,817,000,0003,106,000,0003,198,000,0003,215,000,0001,647,000,0001,624,000,0001,837,000,0002,096,000,0002,104,000,0001,868,000,0002,222,000,0001,211,000,0001,726,000,000
Dividend
Aug 30, 20240.29 USD/sh
Earnings
Feb 06, 2025

Profile

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
URL
https://www.baxter.com/
IPO date
May 15, 1961
Employees
60,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
14,813,000
-1.99%
15,113,000
18.22%
12,784,000
9.52%
Cost of revenue
14,443,000
14,208,000
11,080,000
Unusual Expense (Income)
NOPBT
370,000
905,000
1,704,000
NOPBT Margin
2.50%
5.99%
13.33%
Operating Taxes
(34,000)
68,000
182,000
Tax Rate
7.51%
10.68%
NOPAT
404,000
837,000
1,522,000
Net income
2,656,000
-209.71%
(2,421,000)
-288.55%
1,284,000
16.52%
Dividends
(586,000)
(573,000)
(530,000)
Dividend yield
3.00%
2.23%
1.22%
Proceeds from repurchase of equity
95,000
11,736,000
BB yield
-0.37%
-26.91%
Debt
Debt current
2,796,000
1,525,000
639,000
Long-term debt
12,134,000
16,265,000
18,321,000
Deferred revenue
46,000
80,000
84,000
Other long-term liabilities
1,244,000
1,181,000
1,447,000
Net debt
11,542,000
15,825,000
15,855,000
Cash flow
Cash from operating activities
1,726,000
1,211,000
2,222,000
CAPEX
(692,000)
(679,000)
(743,000)
Cash from investing activities
3,213,000
(931,000)
(11,200,000)
Cash from financing activities
(3,489,000)
(1,438,000)
8,245,000
FCF
658,000
426,000
599,000
Balance
Cash
3,194,000
1,718,000
2,951,000
Long term investments
194,000
247,000
154,000
Excess cash
2,647,350
1,209,350
2,465,800
Stockholders' equity
13,309,000
10,962,000
14,412,000
Invested Capital
21,474,650
22,905,650
26,232,200
ROIC
1.82%
3.41%
7.66%
ROCE
1.51%
3.65%
5.75%
EV
Common stock shares outstanding
506,000
504,000
508,000
Price
38.66
-24.15%
50.97
-40.62%
85.84
6.98%
Market cap
19,561,960
-23.85%
25,688,880
-41.09%
43,606,720
5.12%
EV
31,169,960
41,575,880
59,505,720
EBITDA
1,633,000
2,308,000
2,594,000
EV/EBITDA
19.09
18.01
22.94
Interest
512,000
395,000
192,000
Interest/NOPBT
138.38%
43.65%
11.27%